|Fate||closed February 21, 2008|
|Headquarters||Fairfield Township, Essex County, New Jersey|
|Daniel Glassman (CEO)|
|Products||Adoxa, Zoderm, Pamine Forte, Kerol|
|Revenue||US$145 million (2006)|
Number of employees
|300 (as of December 31, 2006)|
The company marketed to niche physician specialties in the U.S. and 38 international markets. Bradley Pharmaceuticals comprised Doak Dermatologics, specialized in therapies for dermatology and podiatry; Kenwood Therapeutics, providing gastroenterology, OB/GYN and other internal medicine brands; and A. Aarons, which markets authorized generic versions of Doak and Kenwood therapies.
Doak Dermatologics was the division of Bradley Pharmaceuticals that marketed products to dermatologists. Its flag products were Zoderm which is a topical anti-acne product. Adoxa (doxycycline) was an antibiotic intended to treat mild to severe acne.
Kenwood was the affiliate brand that worked with therapeutic products. Among the most prescribed ones were Entsol which is a respiratory therapeutic product and Pamine which is intended to treat digestive problems.
The company was publicly traded at the NYSE by its code BDY since May 2003.
- "Company Overview of Bradley Pharmaceuticals, Inc". Bloomberg Businessweek. September 17, 2014.
- "Fougera which acquired Nycomed)". Archived from the original (PDF) on 23 July 2012.